Antinuclear antibodies in patients with cervical lesions and invasive cervical cancer

2019 ◽  
Vol 208 ◽  
pp. 8-10
Author(s):  
Thelma L. Skare ◽  
Aline Neppel ◽  
Mariana C.C. Machoski ◽  
Carlos A. Maestri ◽  
Iara Messias-Reason ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Antinuclear Antibodies ◽  
Invasive Cervical Cancer ◽  
Cervical Lesions

scholarly journals Clinical Significance of the Interaction between Human Papillomavirus (HPV) Type 16 and Other High-Risk Human Papillomaviruses in Women with Cervical Intraepithelial Neoplasia (CIN) and Invasive Cervical Cancer

2020 ◽  
Vol 2020 ◽  
pp. 1-9
Author(s):  
Arsenio A. Spinillo ◽  
Mattia M. Dominoni ◽  
Anna A. C. Boschi ◽  
Cecilia C. Sosso ◽  
Giacomo G. Fiandrino ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
High Risk ◽  
Residual Disease ◽  
Invasive Cervical Cancer ◽  
Intraepithelial Neoplasia ◽  
Human Papillomaviruses ◽  
Multiple Infections ◽  
Cervical Lesions ◽  
Hpv 16 ◽  
The Impact

The aim is to evaluate the clinical consequences of coinfection between HPV 16 and other high-risk HPVs among women with a histological diagnosis of CIN or invasive cervical cancer. A total of 2985 women, with a diagnosis of either CIN or cancer (<IB) on cervical or cone biopsy, were included. HPV genotypes were identified using the INNO-LiPA HPV genotyping assay, version EXTRA, on cervical scraping, before the colposcopic evaluation and the colposcopic biopsies or conization. In the overall population, HPV16 interacted positively with HPV18 (RR = 2, 95% CI 1.5–2.6) and negatively with HPV33, 51, 52, and 66, in log-linear analysis. There was an excess of CIN3 diagnoses among subjects coinfected with HPV16 and HPV18 or HPV52, although the absolute number of cases was relatively small. In a logistic model, the odds ratio of CIN3+ associated with coinfection of HPV16 and HPV18 (OR = 3.8, 95% CI 2.5–5.7, p = 0.004 compared to single HPV16) or HPV52 (OR = 3.6, 95% CI 2.6–5.1, p = 0.009 compared to single HPV) was higher than that associated with single HPV 16 infections. Finally, multiple infections had no effect on residual disease and did not influence the recurrence of high-grade CIN during a median follow-up of 25 months (IR 17–41). HPV16 interacted positively with HPV18 and negatively with HPV33, 51, 52, and 66 supporting the notion that HPV16 interacts mostly negatively with other HR-HPVs in CIN lesions. Among specimens coinfected with HPV16 and 18 or 52, there was an excess of CIN3+ although the impact on the prevalence of severe cervical lesions was limited.

microRNA Levels in Cervical Cancer Samples and Relationship with Lesion Grade and HPV Infection

MicroRNA ◽  
2021 ◽  
Vol 10 ◽  
Author(s):  
Carolina R. Hoelzle ◽  
Solène Arnoult ◽  
Cinthya R.M. Borém ◽  
Mariana Ottone ◽  
Kênia C.S.F. de Magalhães ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Cancer Progression ◽  
Invasive Cervical Cancer ◽  
Rna Extraction ◽  
Hpv Infection ◽  
Control Group ◽  
Plasma Samples ◽  
Cervical Lesions ◽  
Dna And Rna ◽  
Cervical Scraping

Background: miR-21, miR-214, and miR-let-7a are three validated and well-known miRNAs. miR-21 is described as an “oncomir,” while miR-214 and miR-let-7a are described mainly as tumor suppressors. The role of these miRNAs remains unclear in cervical cancer, an important malignancy among women worldwide and responsible for many deaths every year. Objective: The objective of this study was to describe the expression profile of miR-21, miR-214, and miR-let-7a in plasma and cervical scraping from a control group and patients with different grades of cervical lesions and invasive cervical cancer, and then correlate with HPV infection groups. Methods: Plasma and cervical scraping were submitted to DNA and RNA extraction. HPV detection and typing were performed by conventional PCR followed by PAGE to amplicons interpretation. The miRNA relative expression in plasma and cervical scraping samples was performed by real-time PCR using specific TaqMan probes. Results: miR-21 (p=0.0277) and miR-214 (p=0.0151) were up-regulated in cervical scraping samples of the invasive cervical cancer (ICC) group. However, miR-214 was also up-regulated in the LSIL group (p=0.0062). Both miRNAs were not related to HPV infection. However, miR-let-7a was higher in HPV positive plasma samples (p=0.0433) than in HPV negative plasma samples, and the correlation analysis confirmed the association between the levels of this miRNA with the presence of HPV (p=0.0407; r=0.3029), but not with lesion grade (p>0.05). Conclusion: Our results suggest that miR-21 is related to cervical cancer progression and miR-214 appears to have an ambiguous role in cervical lesions. miR-let-7a may be upregulated at the systemic level in patients with HPV infection.

scholarly journals The European Society of Gynaecological Oncology/European Society for Radiotherapy and Oncology/European Society of Pathology Guidelines for the Management of Patients With Cervical Cancer

2018 ◽  
Vol 28 (4) ◽  
pp. 641-655 ◽  
Author(s):  
David Cibula ◽  
Richard Pötter ◽  
François Planchamp ◽  
Elisabeth Avall-Lundqvist ◽  
Daniela Fischerova ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
European Society ◽  
Invasive Cervical Cancer ◽  
Locally Advanced ◽  
Evidence Based ◽  
Cervical Lesions ◽  
Gynaecological Oncology ◽  
Cancer Management ◽  
Fertility Sparing ◽  
Development Group

BackgroundDespite significant advances in the screening, detection, and treatment of preinvasive cervical lesions, invasive cervical cancer is the fifth most common cancer in European women. There are large disparities in Europe and worldwide in the incidence, management, and mortality of cervical cancer.ObjectiveThe European Society of Gynaecological Oncology (ESGO), the European Society for Radiotherapy and Oncology (ESTRO), and the European Society of Pathology (ESP) jointly develop clinically relevant and evidence-based guidelines in order to improve the quality of care for women with cervical cancer across Europe and worldwide.MethodsThe ESGO/ESTRO/ESP nominated an international multidisciplinary development group consisting of practicing clinicians and researchers who have demonstrated leadership and expertise in the care and research of cervical cancer (23 experts across Europe). To ensure that the guidelines are evidence based, the current literature identified from a systematic search was reviewed and critically appraised. In the absence of any clear scientific evidence, judgment was based on the professional experience and consensus of the development group. The guidelines are thus based on the best available evidence and expert agreement. Prior to publication, the guidelines were reviewed by 159 international reviewers, selected through ESGO/ESTRO/ESP and including patient representatives.ResultsThe guidelines cover comprehensively staging, management, and follow-up for patients with cervical cancer. Management includes fertility sparing treatment; stage T1a, T1b1/T2a1, clinically occult cervical cancer diagnosed after simple hysterectomy; early and locally advanced cervical cancer; primary distant metastatic disease; cervical cancer in pregnancy; and recurrent disease. Principles of radiotherapy and pathological evaluation are defined.

Radical hysterectomy for cervical cancer amongst women infected with the human immunodeficiency virus

2007 ◽  
Vol 17 (6) ◽  
pp. 1264-1265 ◽  
Author(s):  
M. Moodley
Keyword(s):  
South Africa ◽  
Cervical Cancer ◽  
Human Immunodeficiency Virus ◽  
Radical Hysterectomy ◽  
Early Stage ◽  
Invasive Cervical Cancer ◽  
Cervical Lesions ◽  
Stage Disease ◽  
Immunodeficiency Virus ◽  
Late Stage Disease

Invasive cervical cancer and human immunodeficiency virus (HIV) infection are an epidemic in South Africa. Most HIV-infected patients with cervical cancer present with late-stage disease. Whilst the literature describes the outcome of such women with preneoplastic cervical lesions, the management of early-stage invasive cervical cancer and HIV is lacking. We present our experience with such patients

Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: A meta-analysis update

2007 ◽  
Vol 121 (3) ◽  
pp. 621-632 ◽  
Author(s):  
Jennifer S. Smith ◽  
Lisa Lindsay ◽  
Brooke Hoots ◽  
Jessica Keys ◽  
Silvia Franceschi ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Human Papillomavirus ◽  
Meta Analysis ◽  
Invasive Cervical Cancer ◽  
High Grade ◽  
Cervical Lesions ◽  
Type Distribution

scholarly journals Genotyping of human papillomavirus in cervical lesions by L1 consensus PCR and the Luminex xMAP system

2006 ◽  
Vol 55 (6) ◽  
pp. 715-720 ◽  
Author(s):  
Han-Liang Jiang ◽  
Hai-Hong Zhu ◽  
Lin-Fu Zhou ◽  
Feng Chen ◽  
Zhi Chen
Keyword(s):  
Cervical Cancer ◽  
Human Papillomavirus ◽  
High Risk ◽  
High Throughput ◽  
Invasive Cervical Cancer ◽  
Low Risk ◽  
Cervical Lesions ◽  
Suspension Array ◽  
Hpv Genotypes ◽  
High Risk Hpv

Infection with human papillomavirus (HPV) is the main cause of cervical cancer, the principal cancer in women in most developing countries. Molecular epidemiologic evidence clearly indicates that certain types of HPV are the principal cause of invasive cervical cancer and cervical intraepithelial neoplasia. Comprehensive, high-throughput typing assays for HPV, however, are not currently available. By combining L1 consensus PCR and multiplex hybridization using a Luminex xMAP system-based suspension array, the authors developed a rapid high-throughput assay, the HPV DNA suspension array (HPV-SA), capable of simultaneously typing 26 HPVs, including 18 high-risk HPV genotypes and eight low-risk HPV genotypes. The performance of the HPV-SA applied to 26 synthetic oligonucleotide targets was evaluated. The HPV-SA system perfectly discriminated 18 high-risk HPV targets from eight low-risk HPV targets. To assess the clinical applicability of the assay, the HPV-SA was performed with 133 MY09/MY11 primer set-mediated PCR (MY-PCR)-positive clinical specimens; of the 133 samples, 121 were positive by HPV-SA. Both single and multiple types were easily identified. The authors believe that improvement of the assay may be useful for epidemiological studies, cancer-screening programmes, the monitoring of therapeutic interventions, and the evaluation of the efficacy of HPV vaccine trials.

scholarly journals How Liquid Based Cytology Surpasses Conventional Cytology - A Review Article

2021 ◽  
pp. 469-471
Author(s):  
Devikala Kumaresan
Keyword(s):  
Cervical Cancer ◽  
Pap Smear ◽  
Screening Tool ◽  
Precancerous Lesions ◽  
Invasive Cervical Cancer ◽  
Review Article ◽  
Cervical Smear ◽  
Cervical Lesions ◽  
Conventional Cytology ◽  
Liquid Based Cytology

Pap smear is the most widely used test for screening of cervical cancer and precancerous lesions. Liquid-based cytology is a cervical cancer screening technology that inspects cells by dissolving them in liquid and is used as a main screening tool for invasive cervical cancer. The purpose of this article is to demonstrate how fluid-based cytology has surpassed conventional cytology in the interpretation of cervical smear biopsy results in order to identify early cervical lesions in a more efficient and convenient manner, allowing for early diagnosis and treatment of cervical cancer patients and thus improving patient wellbeing.

scholarly journals Nationwide Rereview of Normal Cervical Cytologies before High-Grade Cervical Lesions or before Invasive Cervical Cancer

2021 ◽  
pp. 1-8
Author(s):  
Henrik Edvardsson ◽  
Jiangrong Wang ◽  
Bengt Andrae ◽  
Pär Sparén ◽  
Björn Strander ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Screening Program ◽  
Cervical Screening ◽  
Invasive Cervical Cancer ◽  
False Negative ◽  
Cancer Control ◽  
Adenocarcinoma In Situ ◽  
High Grade ◽  
Cervical Lesions ◽  
Normal Cytology

Sweden has experienced an unexpected &#x3e;30% increase in cervical cancer incidence among women with normal cytological screening results. We therefore performed a nationwide assessment of false-negative cytology before invasive cervical cancer. The Swedish national cervical screening registry identified 2,150 normal cytologies taken up to 10 years before 903 cases of invasive cervical cancer. The 27 cytological laboratories in Sweden were asked to rereview the slides, and all of them completed the rereview. One thousand nine hundred fifteen slides were retrieved and reviewed. Abnormalities were found in 30% of the slides, and the proportion of slides that had a changed diagnosis on rereview increased on average by 3.9% per sampling year during 2001–2016 (<i>p</i> &#x3c; 0.03). We also asked for rereview of normal smears taken up to 42 months before a histopathologically diagnosed high-grade squamous intraepithelial lesion (HSIL) or adenocarcinoma in situ (AIS). 19/27 laboratories responded, and out of 6,101 normal smears taken before HSIL/AIS, 5,918 were retrieved and rereviewed. The diagnosis was changed in 25% of cases. In summary, we found an increasing time trend of false-negative smears taken before invasive cervical cancer. This indicates a decreased protection of normal cytology in the screening program supporting earlier findings that this is the main reason behind the recent Swedish increase in cervical cancer. We suggest that optimal cervical cancer control may be promoted by routine nationally coordinated rereview of negative smears before high-grade cervical lesions or invasive cervical cancer.

Sign in / Sign up

Export Citation Format

Share Document